Safety and Effectiveness of Nivolumab in Recurring Kidney Cancer Participants
NCT03568435 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 212
Last updated 2022-10-20
Summary
A non-interventional, medical record review of clinical data collected from Japanese participants with recurring kidney cancer
Conditions
- Kidney Cancer
- Renal Cancer
Interventions
- OTHER
-
Non-Interventional
Non-Interventional
Sponsors & Collaborators
-
Ono Pharma USA Inc
collaborator INDUSTRY - lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-02-14
- Primary Completion
- 2020-12-21
- Completion
- 2020-12-21
Countries
- Japan
Study Locations
More Related Trials
-
Retrospective Study on the Safety of Nivolumab in Patients With mRCC and Renal Failure
NCT07117409 ·Status: TERMINATED
-
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
NCT02231749 ·Status: COMPLETED ·Phase: PHASE3
-
Nivolumab Plus Stereotactic Body Radiotherapy in II and III Line of Patients With Metastatic Renal Cell Carcinoma
NCT03469713 ·Status: COMPLETED ·Phase: PHASE2
-
BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)
NCT01354431 ·Status: COMPLETED ·Phase: PHASE2
-
Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen
NCT03013335 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)
NCT03203473 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Non-Interventional Study (NIS) of Nivolumab With or Without Ipilimumab in Participants With Advanced Kidney Cancer
NCT03455452 ·Status: ACTIVE_NOT_RECRUITING
-
A Study of the Effectiveness of Cabozantinib in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma (aRCC) in Adults
NCT05361434 ·Status: ACTIVE_NOT_RECRUITING
-
Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients
NCT06345183 ·Status: COMPLETED
-
Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma
NCT03117309 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer
NCT03873402 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy
NCT03055013 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Nivolumab in Treating Patients With High-Risk Kidney Cancer Before Surgery
NCT02595918 ·Status: TERMINATED ·Phase: PHASE1
-
A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma
NCT03635892 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Safety and Compliance of Renal Cancer Patients Treated by Non-IV Drugs
NCT03630692 ·Status: UNKNOWN
-
Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)
NCT01668784 ·Status: COMPLETED ·Phase: PHASE3
-
RAD001 for Non-clear Cell Renal Cell Carcinoma (RCC)
NCT00830895 ·Status: COMPLETED ·Phase: PHASE2
-
CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer
NCT06399419 ·Status: RECRUITING ·Phase: PHASE1
-
Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab
NCT03126331 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC
NCT05663710 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India
NCT04513522 ·Status: COMPLETED ·Phase: PHASE4
-
A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases
NCT05048212 ·Status: RECRUITING ·Phase: PHASE2
-
A Clinical Study of 6MW3211 in Patients With Renal Cancer
NCT05440045 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma
NCT04088500 ·Status: TERMINATED ·Phase: PHASE2
-
Study of CP-461 in Patients With Advanced Renal Cell Cancer
NCT00036036 ·Status: COMPLETED ·Phase: PHASE2